Table 2.
Prevalence of HER2 amplification in metastatic and localized extramammary Paget’s disease
| First author | Year | No. of patients | Stage | HER2 positive | Detection methods |
|---|---|---|---|---|---|
| Takata [92] | 1999 | 27 | Localized | 6 (22%) | IHC, FISH |
| 4 | LNM | 2 (50%) | |||
| Tanskanen [93] | 2003 | 21 | Localized | 11 (52%) | ICH, FISH |
| 2 | LNM | 1 (50%) | |||
| Brummer [94] | 2004 | 10 | Localized | 8 (80%) | IHC |
| Reich [95] | 2005 | 6 | Localized | 4 (66.7%) | FISH |
| Ogawa [91] | 2005 | 34 | Localized | 3 (8.8%) | IHC |
| Bianco [96] | 2006 | 15 | Localized | 1 (6.67%%) | IHC, CISH |
| Plaza [97] | 2009 | 47 | Localized | 15 (32%) | IHC |
| Richter [98] | 2010 | 33 | Localized | 19 (57.6%) | IHC, FISH |
| Miyamoto [99] | 2010 | 23 | Localized | 13 (69.5%) | IHC, FISH |
| 9 | Metastatic | 7 (77.7%) | |||
| Hikita [100] | 2012 | 17 | Localized | 4 (23.5%) | IHC, FISH |
| Tanaka [101] | 2013 | 78 | Localized | 8 (10%) | IHC, FISH |
| 26 | Metastatic | 4 (15%) | |||
| Kang [102] | 2015 | 227 | Localized | 45 (18.3%) | IHC |
| 19 | LNM | ||||
| Hirai [88] | 2019 | 47 | Metastatic | 23 (49%) | IHC, FISH |
| Lu [103••] | 2019 | 11 | Metastatic | 3 (27.2%) | FISH |
| Total | 486 | Localized | 137 (28.2%) | ||
| 99 | Metastatic and LNM | 40 (40%) | |||
LNM, lymph node metastases; IHC, immunohistochemistry; FISH, fluorescent in situ hybridization; CISH, chromogenic in situ hybridization